It's a bit of both of these factors, but mainly the uncertainty. As you know, uncertainty is the worst enemy of investors and companies, particularly pharmaceutical companies, which don't know what to do at the moment. They are very much afraid that the reform would reduce expected profits, which would make it more difficult to launch medicines in a timely manner in Canada.
Of course, as I mentioned in my first address, Canada is not the only potential market. We only have a very small share of the global market in pharmaceuticals. The companies will very likely focus on other places where the conditions are more conducive to the launch of new medicines.